For research use only.
CAS No. 1082949-67-4
LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
Selleck's LY2584702 has been cited by 10 publications
5 Customer Reviews
Murine DCs were pretreated with PBS or kinase inhibitors (10 μmol/l) wortmanni LY2584702 2 h prior to nicotine (10−7 mol/l) 12~15 h stimulation. MR expression was determined via western blot analyses (C, F). β-actin was used as an internal control.
Oncotarget, 2016, 7(25):38451-38466. LY2584702 purchased from Selleck.
(A) Flow cytometry for TNF-α and IL-12 p40 intracellular expression and ELISA assays for IL-12p70 and IL-23 in supernatants of untreated or treated cells after 24 h. Results were expressed as pictograms per milliliter (± SD) from four independent experiments, each performed in triplicate. *p < 0.05 versus IFN-γ, **p < 0.01 versus IFN-γ.
J Immunol, 2016, 197(9):3545-3553. LY2584702 purchased from Selleck.
Peripheral blood monocytes were mock or HCMV infected, or treated with GMCSF or M-CSF for 30 min. Levels of p-S6K (T389), and S6K were detected by immunoblotting from whole cell lysates. Membranes were then reprobed for β-actin as a loading control. Data are representative of 3-6 independent blood donors.
Antiviral Res, 2018, 158:13-24. LY2584702 purchased from Selleck.
Pre-warmed human neutrophil suspensions (37°C, 5 million cells/ml in HBSS containing 1.6 mM CaCl2) were incubated with PF-4708671, LY2584702 or vehicle (DMSO) for 5 minutes, then stimulated with 100 nM thapsigargin for 10 minutes. B) Samples were processed and analyzed for S6 and phospho-S6 content as described in methods. Data are from one experiment, representative of three.
PLoS One, 2017, 12(1):e0169804. LY2584702 purchased from Selleck.
Western blot analysis of RPS6KB1, p-RPS6KB1, rpS6 and p-rpS6 in adenocarcinoma cell line A549 and squamous cell carcinoma cell line SK-MES-1 with various LY2584702 concentrations. DMSO without any LY2584702 were expressed as a concentration of 0. β-actin was used as a loading control.
PLoS One, 2017, 12(8):e0182891. LY2584702 purchased from Selleck.
Purity & Quality Control
Choose Selective S6 Kinase Inhibitors
|Description||LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.|
In HCT116 colon cancer cells, LY2584702 inhibits phosphorylation of the S6 ribosomal protein (pS6) with IC50 of 0.1-0.24 μM.  LY2584702 has significant synergistic effects when combined with EGFR inhibitor erlotinib or with the mTOR inhibitor everolimus. 
|In vivo||LY2584702 (12.5 mg/kg BID), demonstrates significant antitumor efficacy in both U87MG glioblastoma and HCT116 colon carcinoma xenograft models. |
|In vitro||DMSO||1 mg/mL warmed (2.24 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Frequently Asked Questions
what is the difference between S7698 and S7704? Ie., what does the tosylate group do?
S7698 is the free base of the compound and S7704 is its tosylate salt. Chemically, salt form is more stable and has a better solubility than free base, however, it also has a higher molecular weight. Biologically, these two forms have the same activities.